Article

Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer

2023-04-25

Abstract excerpt

Prostate cancer (PCa) remains the most diagnosed non-skin cancer amongst the American male population. Treatment for localized prostate cancer consists of androgen deprivation therapies (ADTs), which typically inhibit androgen production and the androgen receptor (AR). Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to castration-resistant prostate ca...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 43559980-8833-5a58-9c13-5473e0efa574
DOI: 10.1101/2023.04.22.537922

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancerDOI 10.1101/2023.04.22.537922Read

Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancerSemantic proximity Read

Persistent androgen receptor addiction in castration-resistant prostate cancerSemantic proximity Read

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.Semantic proximity Read

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal DomainSemantic proximity Read

High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.Semantic proximity Read

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read

The mechanistic role of long non-coding RNAs in advanced prostate cancer response to therapySemantic proximity Read

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2 -altered Prostate TumorsSemantic proximity Read

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read